PDGFR-IN-1(compound 7m)是一种口服有效的 PDGFR(血小板源性生长因子受体)抑制剂,对 PDGFRα 和 PDGFRβ 的 IC50 分别为 2.4 和 0.9 nM,具有较强的抗肿瘤作用和低毒性,可用于骨肉瘤的研究。
产品编号: MS-E88892 纯度: 98.84% CAS No.: 2644673-07-2 分子式: C25H30N8O 分子量: 458.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

PDGFR-IN-1(compound 7m)是一种口服有效的 PDGFR(血小板源性生长因子受体)抑制剂,对 PDGFRα 和 PDGFRβ 的 IC50 分别为 2.4 和 0.9 nM,具有较强的抗肿瘤作用和低毒性,可用于骨肉瘤的研究。

生物实验数据

生物活性 PDGFR-IN-1 (compound 7m) is an orally active PDGFR (platelet-derived growth factor receptor) inhibitor with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively, and exhibits potent antitumor activity and low toxicity, making it suitable for research on osteosarcoma.
IC50 & Target PDGFRα:2.4 nM, PDGFRβ:0.9 nM
体外研究
(In Vitro)

PDGFR-IN-1 (compound 7m) (0-0.4 μM, 48 h) inhibits osteosarcoma cancer cells (U2OS, MG63, MNNG/HOS, and SAOS-2) proliferation and colony formation.
PDGFR-IN-1 (0-0.4 μM, 48 h) induces cell-cycle arrest in a dose-dependent manner.
PDGFR-IN-1 (0-1.6 μM, 48 h) induces MNNG/HOS and MG63 cell apoptosis in a dose-dependent manner.
PDGFR-IN-1 (0-0.4 μM, 15 min) inhibits the expression of α-tubulin in both MNNG/HOS and MG63 cells.
PDGFR-IN-1 (0-0.4 μM, 48 h) inhibits PDGFRβ phosphorylation and downstream signaling transduction (p-STAT3, p-AKT, and p-ERK).
PDGFR-IN-1 (0-0.4 μM, 48 h) significantly inhibits osteosarcoma cancer cell migration and invasion by downregulating the expression of FAK, as well as the distribution in the leading edge of cells.

Cell Proliferation Assay

Cell Line: Human osteosarcoma cancer cell lines (U2OS, MG63, MNNG/HOS, and SAOS-2)
Concentration: 0.1, 0.2, and 0.4 μM.
Incubation Time: 48 h
Result: Showed strong antiproliferative activity against MG63, U2OS, MNNG/HOS, and SAOS-2, with IC50 values of 0.44, 0.42, 1.03, and 0.37 μM, respectively. Showed dose-dependent inhibition colony formation.

Cell Cycle Analysis

Cell Line: MG63 and MNNG/HOS cells
Concentration: 0, 0.1, 0.2, 0.4 μM
Incubation Time: 48 h
Result: Induced G2/M cell-cycle arrest in MNNG/HOS and G0/G1 cell-cycle arrest in MG63 cells in a dose-dependent manner.

Apoptosis Analysis

Cell Line: MG63 and MNNG/HOS cells
Concentration: 0, 0.4, 0.8, 1.6 μM
Incubation Time: 48 h
Result: Induced MNNG/HOS and MG63 cell apoptosis in a dose-dependent manner.

Immunofluorescence

Cell Line: MG63 and MNNG/HOS
Concentration: 0, 0.1, 0.2, 0.4 μM
Incubation Time: 15 min
Result: Inhibited the expression of α-tubulin in both MNNG/HOS and MG63 cells, inhibited proliferation and reduced the PDGFRβ fluorescence intensity in a concentration-dependent manner.

Western Blot Analysis

Cell Line: MG63 and MNNG/HOS
Concentration: 0, 0.1, 0.2, 0.4 μM
Incubation Time: 48 h
Result: Effective inhibited PDGFRβ phosphorylation and downstream signaling transduction (p-STAT3, p-AKT, and p-ERK) at the cellular level.
体内研究
(In Vivo)

PDGFR-IN-1 (BALB/c mice, MNNG/HOS xenograft mouse, 15, 30 mg/kg, orally, daily for 14 days) significantly suppresses tumor growth, exhibits a stronger antitumor efficacy with low toxicity.
PDGFR-IN-1 (C57/BL6 mice, 40, 80 mg/kg, orally, daily for 10 days) is safe for in vivo investigations.
PDGFR-IN-1 (Sprague-Dawley rats, 20 mg/kg PO or 4 mg/kg IP, once) shows a favorable profile with a high maximum concentration and exposure, an acceptable half-life, and a good oral bioavailability.
Pharmacokinetic Parameters of PDGFR-IN-1 in male Sprague-Dawley rats.

7m
route IP PO
dose (mg/kg) 4 20
Cmax (ng/mL) 78.3 75.2
t1/2 (h) 2.86 2.12
AUC0-∞ (ng/mL*h) 211.3 664.7
F (%) 62.9

Animal Model: Sprague-Dawley rats (male, 200-260 g, Six rats, two groups)
Dosage: 20 mg/kg (PO) or 4 mg/kg (IP)
Administration: PO, IP, once (Pharmacokinetic Analysis)
Result: Showed a favorable profile with a high maximum concentration and exposure, an acceptable half-life, and a good oral bioavailability.
Animal Model: BALB/c mice (18-20 g, MNNG/HOS xenograft mouse, eight groups)
Dosage: 15, 30 mg/kg
Administration: Orally, daily for 14 days
Result: Significantly suppressed tumor growth, exhibited a stronger antitumor efficacy, did not cause significant body weight or organ weight (heart, lung, liver, spleen, or kidney) changes, strongly suppressed the proliferation of tumor cells and induced apoptosis in tissues of the tumor.
Animal Model: C57/BL6 mice
Dosage: 40, 80 mg/kg
Administration: Orally, daily for 10 days
Result: Did not reveal any obvious morphological aberration in organ tissues.
性状 固体
颜色 Light yellow to brown

化学信息

分子量 458.56
分子式 C25H30N8O
CAS No. 2644673-07-2

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.9 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (218.07 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1807 mL10.9037 mL21.8074 mL54.5185 mL
5 mM0.4361 mL2.1807 mL4.3615 mL10.9037 mL
10 mM0.2181 mL1.0904 mL2.1807 mL5.4518 mL
15 mM0.1454 mL0.7269 mL1.4538 mL3.6346 mL
20 mM0.1090 mL0.5452 mL1.0904 mL2.7259 mL
25 mM0.0872 mL0.4361 mL0.8723 mL2.1807 mL
30 mM0.0727 mL0.3635 mL0.7269 mL1.8173 mL
40 mM0.0545 mL0.2726 mL0.5452 mL1.3630 mL
50 mM0.0436 mL0.2181 mL0.4361 mL1.0904 mL
60 mM0.0363 mL0.1817 mL0.3635 mL0.9086 mL
80 mM0.0273 mL0.1363 mL0.2726 mL0.6815 mL
100 mM0.0218 mL0.1090 mL0.2181 mL0.5452 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础